Filipczak- Bryniarska I. (2017, Poland) [23] | Unicentric trial, single-arm | 18 | High-dose 8% Capsaicin patch | Painful peripheral polyneuropathy (clinical history and neurological examination by a neurologist), with NRS ≥4 | Colon cancer, submit to oxaliplatin-based ChT | NRS at baseline and on 1 and 8 days after, and 8 and 12 weeks after | Reduction of NRS score occurred in 84% - 97% of pts, after 12 weeks. | None of the adverse events occurred. | 13 | 1, 2, 4, 5, 6, 9, 10, 13, 14, 16, 17, 18, 19 |
Barton D. L. (2011, USA) [27] | Multicentric, randomized, double-blind, placebo-controlled trial | 208 | Topical BAK gel (baclofen 0.8%, amitriptyline 3% and ketamine 1.5%), bid, for 4 weeks | >1 month symptomatic CIPN, with numbness, tingling or pain level of ≥4 out of 10 | Any cancer and stage. Active or previous treatment with neurotoxic ChT | Sensory subscale of the EORTC QLQ-CIPN20, at baseline and 4 weeks after | A greater improvement for BAK arm (vs. placebo) in the sensory subscale (p = 0.053). | Without undesirable toxicities. No evidence of systemic toxicity. | 12 | 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 16, 19 |
Gewandter J. S. (2014, USA) [28] | Multicentric, phase III randomized, double-blind, placebo-controlledtrial | 462 | Topical KA cream (ketamine 2% and amitriptyline 4%), bid, for 6 weeks | CIPN (pain, numbness, and tingling) ≥ 4 out of 10; ≥1 month beyond ChT completion | Any cancer and stage. Previous treatment with neurotoxic ChT (taxane vs. non-taxane) | Pain, numbness, and tingling scoresat baseline and at 6 weeks after | No effect on 6-week CIPN scores (p = 0.363). | Adverse events occurred at relatively equivalent rates and severity in both arms. | 11 | 2, 3, 4, 5, 6, 7, 8, 9, 13, 16, 18 |
Rossignol J. (2019, France) [24] | Unicentric trial, single-arm, pilot study | 44 | Topical 10% Amitriptyline cream bid | CIPN with NCI-CTCAE v4.0 grade >1 | Haematological or solid tumours. Previous treatment with neurotoxic ChT | VAS on the baseline; and at 1, 2 and 4 weeks; and then monthly up to 1 year | Median VAS score decreased from 7 (4 - 9) to 2 (0 - 4) after 4-week treatment | Discontinuation is only 1 patient (skin irritation) | 11 | 2, 3, 4, 5, 6, 9, 13, 16, 17, 18, 19 |
Prinsloo S. (2017, USA) [22] | Unicentric, randomized, waitlist-controlled trial, pilot study | 62 | Neurofeedback: 20 sessions (twice a week) | CIPN with NCI-CTCAE v4.0 grade ≥3 and/or neuropathic pain (NRS ≥4), for ≥3 months beyond ChT completion | Any cancer and stage. Previous treatment with neurotoxic ChT | BPI-SF worst-pain item, on the baseline and then weekly until the end | Decrease in BPI-SF worst pain (mean change score: −2.43 vs. 0,09, p = 0.001) | All pts completed NFB treatment, without discontinuation problem or side effects | 13 | 1, 2, 3, 4, 5, 7, 9, 12, 13, 16, 17, 18, 19 |